RhumbLine Advisers
VOR icon

RhumbLine Advisers’s Vor Biopharma VOR Stock Holding History

RhumbLine Advisers’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-275
Closed -$5.5K – 4337
2024
Q2 		$5.5K Sell
275
-1,909
-87% -$61.7K ﹤0.01% 4072
2024
Q1 		$103K Buy
2,184
+34
+2% +$1.49K ﹤0.01% 3438
2023
Q4 		$96.7K Sell
2,150
-95
-4% -$3.92K ﹤0.01% 3459
2023
Q3 		$95.2K Buy
2,245
+114
+5% +$6.18K ﹤0.01% 3478
2023
Q2 		$132K Buy
+2,131
New +$195K ﹤0.01% 3422
2022
Q2 		– Sell
-817
Closed -$99K – 3245
2022
Q1 		$99K Sell
817
-100
-11% -$17K ﹤0.01% 2887
2021
Q4 		$213K Buy
917
+147
+19% +$42.4K ﹤0.01% 2818
2021
Q3 		$242K Buy
770
+193
+33% +$57.4K ﹤0.01% 2846
2021
Q2 		$215K Buy
577
+97
+20% +$47.9K ﹤0.01% 2907
2021
Q1 		$414K Buy
+480
New +$406K ﹤0.01% 2573

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RhumbLine Advisers's VOR Position: Q3 2024 in Review

RhumbLine Advisers sold out of Vor Biopharma (VOR) in Q3 2024, closing a stake of 275 shares — an estimated $5.5K sold.

RhumbLine Advisers first reported a position in VOR in Q1 2021 and held it in 10 quarters. The position peaked at $414K in Q1 2021. 54 funds tracked by Wall St. Rank hold VOR as of Q3 2024.

  • RhumbLine Advisers reported no remaining Vor Biopharma position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 275 Vor Biopharma shares in Q3 2024, an estimated $5.5K.
  • RhumbLine Advisers first reported a position in Vor Biopharma in Q1 2021 and held it in 10 quarters.
  • RhumbLine Advisers's Vor Biopharma position peaked at $414K in Q1 2021.
  • 54 funds tracked by Wall St. Rank held Vor Biopharma as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.